Archive
This is my archive
Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetes
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock… Read More
Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors
Financing Fuels the Company’s Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic’s Appointment Positions Imperative Care for Long Term Success and Scale July 25, 2024 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a medical technology company developing connected innovations to… Read More
Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases
Company’s first-in-class PDE9 inhibitor for heart failure and first-in-class CaMKII inhibitor move into later-stage clinical trials in cardiovascular diseases Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug innovator Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug innovator July… Read More
Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases
Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight Company is developing a new class of genomic medicines based on naturally occurring genetic elements that may be… Read More
AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program
Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital, Delos Capital and existing investors aMoon Fund and Blackstone Multi-Asset Investing, among other new and existing investors Funds will be used to support ongoing and planned Phase 2a and 2b clinical… Read More
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to support ongoing mid- to late-stage clinical development programs for Company’s lead I&I product candidate, obexelimab WALTHAM, Mass, May 7, 2024 (GLOBE NEWSWIRE) – Zenas BioPharma,… Read More
Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
Financing includes nine new investors and was led by New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and Sands Capital Proceeds to support advancing AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor SAN DIEGO, Calif., March 26, 2024 – Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next… Read More
Sirius Therapeutics Raised Nearly US$100 Million to Accelerate Clinical Development of siRNA Therapeutics
October 9, 2023, San Diego and Shanghai – Sirius Therapeutics today announced that it has completed a US$60 million Series B financing to advance the clinical development of the Company’s novel siRNA therapeutics and the continued innovation of the next-generation RNA delivery technologies. This financing round was led by Hankang… Read More